Determination of alpha-N-acetamino galactosidase activity

Abstract

The vitamin D binding protein (Gc protein) and its small region (approximately 1 / 5 of the Gc peptide, known as region III) were cloned with the aid of baculovirus vectors. The cloned Gc protein and cloned domain (Cd) peptide were treated with immobilized β-galactosidase and sialidase to produce macrophage activating factors GcMAFc and CdMAF, respectively. These cloned macrophage activating factors and GcMAFs can be used to treat cancer, HIV infection, and osteoporosis, as well as as adjuvants for immunization and vaccination. Methods and antibody-sandwich ELISA kits for detecting serum or plasma α-N-acetylgalactosaminidase activity in patients with cancer and HIV infection were developed.

Description

[0001] This application is a divisional application of an invention patent application with an application date of June 5, 1996, an application number of 96195808.1, and an invention title of "macrophage activating factor derived from cloned vitamin D binding protein". technical field

[0002] The present invention relates to the use of cloned vitamin D binding protein (Gc protein) and oligosaccharide digestion of cloned Gc protein domain III to produce potent macrophage activating factors and the role of these macrophage activating factors in various cancers, HIV applications in infection and osteoporosis, and as an adjuvant in immunizations and vaccinations, has also developed the use of a specific enzyme detected in the blood of cancer and HIV-infected patients, α-N-acetylaminosemi Diagnostic and prognostic methods of lactosinase.

[0003] the term

[0004] Gc protein vitamin D 3 binding protein

[0005] MAF macrophage activating factor

[0006] GcMAF Gc protein-derived...

Images